Synergistic malaria vaccine combinations identified by systematic antigen screening

Proceedings of the National Academy of Sciences of the United States of America

Volumn 114, Issue 45, 2017, Pages 12045-12050

  Bustamante, Leyla Y ^a,f   Powell, Gareth T ^a,g   Lin, Yen Chun ^b   Macklin, Michael D ^c   Cross, Nadia ^a   Kemp, Alison ^a   Cawkill, Paula ^a   Sanderson, Theo ^a   Crosnier, Cecile ^a   Muller Sienerth, Nicole ^a   Doumbo, Ogobara K ^d   Traore, Boubacar ^d   Crompton, Peter D ^e   Cicuta, Pietro ^b   Tran, Tuan M ^c   Wright, Gavin J ^a   Rayner, Julian C ^a  

^a WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Université des Sciences des Techniques et des Technologies de Bamako   (Mali)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Antigen combinations; Erythrocyte invasion; Malaria; Plasmodium falciparum; Vaccine

Indexed keywords

MALARIA VACCINE; PARASITE ANTIGEN; PROTOZOAL PROTEIN; PROTOZOON ANTIBODY;

ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; DEVELOPMENTAL STAGE; DRUG POTENTIATION; ERYTHROCYTE; HUMAN; HUMAN CELL; NONHUMAN; PLASMODIUM; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; VIDEO MICROSCOPY; CELL LINE; HEK293 CELL LINE; IMMUNOLOGY; MALARIA FALCIPARUM; PARASITOLOGY; PROSPECTIVE STUDY;

ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CELL LINE; ERYTHROCYTES; HEK293 CELLS; HUMANS; MALARIA VACCINES; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; PROSPECTIVE STUDIES; PROTOZOAN PROTEINS;

EID: 85033437474     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1702944114     Document Type: Article

References (38)

1. WHO (2015) WHO World Malaria Report 2015. Available at www.who.int/malaria/publications/world-malaria-report-2015/en/. Accessed October 10, 2017.
2. Bhatt S, et al. (2015) The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015. Nature 526:207–211.
3. Ashley EA, et al.; Tracking Resistance to Artemisinin Collaboration (TRAC) (2014) Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 371:411–423.
4. RTS,S Clinical Trials Partnership (2015) Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: Final results of a phase 3, individually randomised, controlled trial. Lancet 386:31–45.
5. Neafsey DE, et al. (2015) Genetic diversity and protective efficacy of the RTS,S/ AS01 malaria vaccine. N Engl J Med 373:2025–2037.
6. MalariaGEN Plasmodium falciparum Community Project (2016) Genomic epidemiology of artemisinin resistant malaria. Elife 5:e08714.
7. WHO (2013) Malaria Vaccine Technology Roadmap. Available at www.who.int/immunization/topics/malaria/vaccine_roadmap/TRM_update_nov13.pdf?ua=1. Accessed October 10, 2017.
8. Conway DJ (2015) Paths to a malaria vaccine illuminated by parasite genomics. Trends Genet 31:97–107.
9. Hu G, et al. (2010) Transcriptional profiling of growth perturbations of the human malaria parasite Plasmodium falciparum. Nat Biotechnol 28:91–98.
10. Crosnier C, et al. (2013) A library of functional recombinant cell-surface and secreted P. falciparum merozoite proteins. Mol Cell Proteomics 12:3976–3986.
11. Crosnier C, et al. (2011) Basigin is a receptor essential for erythrocyte invasion by Plasmodium falciparum. Nature 480:534–537.
12. Wanaguru M, Crosnier C, Johnson S, Rayner JC, Wright GJ (2013) Biochemical analysis of the Plasmodium falciparum erythrocyte-binding antigen-175 (EBA175)-glycophorin-A interaction: Implications for vaccine design. J Biol Chem 288:32106–32117.
13. Osier FH, et al. (2014) New antigens for a multicomponent blood-stage malaria vaccine. Sci Transl Med 6:247ra102.
14. Durocher Y, Perret S, Kamen A (2002) High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res 30:E9.
15. Theron M, Hesketh RL, Subramanian S, Rayner JC (2010) An adaptable two-color flow cytometric assay to quantitate the invasion of erythrocytes by Plasmodium falciparum parasites. Cytometry A 77:1067–1074.
16. Volkman SK, et al. (2007) A genome-wide map of diversity in Plasmodium falciparum. Nat Genet 39:113–119.
17. Douglas AD, et al. (2011) The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody. Nat Commun 2:601.
18. Bustamante LY, et al. (2013) A full-length recombinant Plasmodium falciparum PfRH5 protein induces inhibitory antibodies that are effective across common PfRH5 genetic variants. Vaccine 31:373–379.
19. Kadekoppala M, O’Donnell RA, Grainger M, Crabb BS, Holder AA (2008) Deletion of the Plasmodium falciparum merozoite surface protein 7 gene impairs parasite invasion of erythrocytes. Eukaryot Cell 7:2123–2132.
20. Adams JH, Blair PL, Kaneko O, Peterson DS (2001) An expanding ebl family of Plasmodium falciparum. Trends Parasitol 17:297–299.
21. Miller SK, et al. (2002) A subset of Plasmodium falciparum SERA genes are expressed and appear to play an important role in the erythrocytic cycle. J Biol Chem 277:47524–47532.
22. Reddy KS, et al. (2015) Multiprotein complex between the GPI-anchored CyRPA with PfRH5 and PfRipr is crucial for Plasmodium falciparum erythrocyte invasion. Proc Natl Acad Sci USA 112:1179–1184.
23. Volz JC, et al. (2016) Essential role of the PfRh5/PfRipr/CyRPA complex during Plasmodium falciparum invasion of erythrocytes. Cell Host Microbe 20:60–71.
24. Nixon CP, et al. (2005) Antibodies to rhoptry-associated membrane antigen predict resistance to Plasmodium falciparum. J Infect Dis 192:861–869.
25. Ogutu BR, et al.; MSP-1 Malaria Vaccine Working Group (2009) Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya. PLoS One 4:e4708.
26. Dreyer AM, et al. (2012) Passive immunoprotection of Plasmodium falciparum-infected mice designates the CyRPA as candidate malaria vaccine antigen. J Immunol 188:6225–6237.
27. Crompton PD, et al. (2010) A prospective analysis of the Ab response to Plasmodium falciparum before and after a malaria season by protein microarray. Proc Natl Acad Sci USA 107:6958–6963.
28. Tran TM, et al. (2014) Naturally acquired antibodies specific for Plasmodium falciparum reticulocyte-binding protein homologue 5 inhibit parasite growth and predict protection from malaria. J Infect Dis 209:789–798.
29. Fivelman QL, Adagu IS, Warhurst DC (2004) Modified fixed-ratio isobologram method for studying in vitro interactions between atovaquone and proguanil or dihydroartemisinin against drug-resistant strains of Plasmodium falciparum. Antimicrob Agents Chemother 48:4097–4102.
30. Weiss GE, et al. (2015) Revealing the sequence and resulting cellular morphology of receptor-ligand interactions during Plasmodium falciparum invasion of erythrocytes. PLoS Pathog 11:e1004670.
31. Crick AJ, et al. (2013) An automated live imaging platform for studying merozoite egress-invasion in malaria cultures. Biophys J 104:997–1005.
32. Zenonos ZA, et al. (2015) Basigin is a druggable target for host-oriented antimalarial interventions. J Exp Med 212:1145–1151.
33. McCarthy JS, et al. (2011) A phase 1 trial of MSP2-C1, a blood-stage malaria vaccine containing 2 isoforms of MSP2 formulated with Montanide ISA 720. PLoS One 6:e24413.
34. Hjerrild KA, et al. (2016) Production of full-length soluble Plasmodium falciparum RH5 protein vaccine using a Drosophila melanogaster Schneider 2 stable cell line system. Sci Rep 6:30357.
35. Ntege EH, et al. (2016) Identification of Plasmodium falciparum reticulocyte binding protein homologue 5-interacting protein, PfRipr, as a highly conserved blood-stage malaria vaccine candidate. Vaccine 34:5612–5622.
36. Saul A (1987) Kinetic constraints on the development of a malaria vaccine. Parasite Immunol 9:1–9.
37. Srinivasan P, et al. (2014) Immunization with a functional protein complex required for erythrocyte invasion protects against lethal malaria. Proc Natl Acad Sci USA 111:10311–10316.
38. Bell A (2005) Antimalarial drug synergism and antagonism: Mechanistic and clinical significance. FEMS Microbiol Lett 253:171–184.